118 related articles for article (PubMed ID: 15171689)
1. Relationship of plasma extracellular-superoxide dismutase level with insulin resistance in type 2 diabetic patients.
Adachi T; Inoue M; Hara H; Maehata E; Suzuki S
J Endocrinol; 2004 Jun; 181(3):413-7. PubMed ID: 15171689
[TBL] [Abstract][Full Text] [Related]
2. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
3. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
Bajaj M; Suraamornkul S; Piper P; Hardies LJ; Glass L; Cersosimo E; Pratipanawatr T; Miyazaki Y; DeFronzo RA
J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
[TBL] [Abstract][Full Text] [Related]
4. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
[TBL] [Abstract][Full Text] [Related]
5. Effects of PPARgamma ligands and C/EBPbeta enhancer on expression of extracellular-superoxide dismutase.
Adachi T; Inoue M; Hara H; Suzuki S
Redox Rep; 2004; 9(4):207-12. PubMed ID: 15479564
[TBL] [Abstract][Full Text] [Related]
6. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
[TBL] [Abstract][Full Text] [Related]
7. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
[TBL] [Abstract][Full Text] [Related]
8. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.
Park JS; Cho MH; Nam JS; Yoo JS; Ahn CW; Cha BS; Kim KR; Lee HC
Eur J Endocrinol; 2011 Jan; 164(1):69-74. PubMed ID: 20961967
[TBL] [Abstract][Full Text] [Related]
9. Lower plasma adiponectin concentration predicts the efficacy of pioglitazone in diabetic patients.
Hiramatsu S; Tajiri Y; Karashima T
Diabetes Obes Metab; 2004 May; 6(3):231-3. PubMed ID: 15056132
[TBL] [Abstract][Full Text] [Related]
10. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
Yu JG; Javorschi S; Hevener AL; Kruszynska YT; Norman RA; Sinha M; Olefsky JM
Diabetes; 2002 Oct; 51(10):2968-74. PubMed ID: 12351435
[TBL] [Abstract][Full Text] [Related]
11. Anti oxidant potential of Metformin and Pioglitazone in Type 2 Diabetes Mellitus: Beyond their anti glycemic effect.
Singh RK; Gupta B; Tripathi K; Singh SK
Diabetes Metab Syndr; 2016; 10(2):102-4. PubMed ID: 26341927
[TBL] [Abstract][Full Text] [Related]
12. Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW.
Tripathy D; Clement SC; Schwenke DC; Banerji M; Bray GA; Buchanan TA; Gastaldelli A; Henry RR; Kitabchi AE; Mudaliar S; Ratner RE; Stentz FB; Musi N; Reaven PD; DeFronzo RA
Diabetes Care; 2014 Jun; 37(6):1706-11. PubMed ID: 24705615
[TBL] [Abstract][Full Text] [Related]
13. Expression of extracellular superoxide dismutase during adipose differentiation in 3T3-L1 cells.
Adachi T; Toishi T; Wu H; Kamiya T; Hara H
Redox Rep; 2009; 14(1):34-40. PubMed ID: 19161676
[TBL] [Abstract][Full Text] [Related]
14. Chemerin and apelin are positively correlated with inflammation in obese type 2 diabetic patients.
Yu S; Zhang Y; Li MZ; Xu H; Wang Q; Song J; Lin P; Zhang L; Liu Q; Huang QX; Wang K; Hou WK
Chin Med J (Engl); 2012 Oct; 125(19):3440-4. PubMed ID: 23044303
[TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
16. Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects.
Tsunekawa T; Hayashi T; Suzuki Y; Matsui-Hirai H; Kano H; Fukatsu A; Nomura N; Miyazaki A; Iguchi A
Diabetes Care; 2003 Feb; 26(2):285-9. PubMed ID: 12547850
[TBL] [Abstract][Full Text] [Related]
17. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
18. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.
Miyazaki Y; Matsuda M; DeFronzo RA
Diabetes Care; 2002 Mar; 25(3):517-23. PubMed ID: 11874940
[TBL] [Abstract][Full Text] [Related]
19. Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension.
Park H; Hasegawa G; Obayashi H; Fujinami A; Ohta M; Hara H; Adachi T; Tamaki S; Nakajima Y; Kimura F; Ogata M; Fukui M; Yoshikawa T; Nakamura N
Clin Chim Acta; 2006 Dec; 374(1-2):129-34. PubMed ID: 16857181
[TBL] [Abstract][Full Text] [Related]
20. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
